Education
About Us
Working with TipRanks
Follow Us
Helix BioMedix (HXBM)
:HXBM
HXBM Stock Chart & Stats
$3.70
$0.00(0.00%)
At close: 4:00 PM EST
$3.70
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$3.39 - $18.00
Previous CloseN/A
Volume13.00
Average Volume (3M)14.00
Market Cap
$830.30K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.05
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding224,708
10 Day Avg. Volume0
30 Day Avg. Volume14
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)1.77
Price to Sales (P/S)5.24
P/FCF Ratio-6.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
HXBM FAQ
What was Helix BioMedix’s price range in the past 12 months?
Helix BioMedix lowest stock price was $3.39 and its highest was $18.00 in the past 12 months.
What is Helix BioMedix’s market cap?
Helix BioMedix’s market cap is $830.30K.
When is Helix BioMedix’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Helix BioMedix’s earnings last quarter?
Currently, no data Available
Is Helix BioMedix overvalued?
According to Wall Street analysts Helix BioMedix’s price is currently Overvalued.
Does Helix BioMedix pay dividends?
Helix BioMedix does not currently pay dividends.
What is Helix BioMedix’s EPS estimate?
Helix BioMedix’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Helix BioMedix have?
Helix BioMedix has 224,708 shares outstanding.
What happened to Helix BioMedix’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Helix BioMedix?
Currently, no hedge funds are holding shares in HXBM
Company Description
Helix BioMedix
Helix BioMedix, Inc. operates as a specialty dermatology and consumer products skin health company in the United States. It develops and commercializes bioactive peptides, including anti-infective, anti-fungal, and anti-inflammatory peptides for the treatment of skin and wound infections, as well as for the prevention of staphylococcus aureus infections. The company also out-licenses its proprietary peptides to various entities. Helix BioMedix, Inc. was founded in 1988 and is headquartered in Bothell, Washington.
Technical Analysis
Q/C Technologies
―
Entero Therapeutics
―
Protagenic Therapeutics
―
ZyVersa Therapeutics
―
PMGC Holdings
―